Singapore-based biotechnology firm Tessa Therapeutics (Tessa) has come a long way from the Singapore cafe where the idea of its inception was hatched.
Born over a discussion eight years ago between an immunologist and an oncologist, it is today ahead in the race to turn cancer patients' own immune cells (T-cells) against the tumours in their bodies.
Already a subscriber? Log in
Get exclusive reports and insights with more than 500 subscriber-only articles every month
No contract
ST app access on 1 mobile device
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you
Join ST's WhatsApp Channel and get the latest news and must-reads.
A version of this article appeared in the print edition of The Sunday Times on March 04, 2018, with the headline Bright sparks in the biomedical sector. Subscribe